Agios Pharmaceuticals, Inc. - Common Stock — Rendiconto Finanziario (NASDAQ:AGIO) | MetaTrader

Apri il grafico completo Full chart

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

Notizie

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class (AGIO)

Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?

Le azioni Dell volano in preborsa; Gap e Firefly Aerospace in calo

Wall Street ferma in attesa di novità dal Medio Oriente

Agios sospende lo sviluppo di tebapivat per i disturbi del sangue

Agios Pharmaceuticals crolla in borsa dopo insuccesso in trial clinico

AGIO's Pyrukynd Gets Approval for Thalassemia in Europe

UE approva mitapivat per il trattamento della talassemia negli adulti

Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease

Agios presenta i dati su mitapivat al congresso europeo di ematologia

Agios presenta domanda per mitapivat nella malattia falciforme

AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum